Fresenius Unveils Sustainable KabiLab D20 to Drive Next-Generation Clinical Nutrition Innovation

Fresenius Unveils Sustainable KabiLab D20 to Drive Next-Generation Clinical Nutrition Innovation

(IN BRIEF) The Fresenius healthcare group is constructing a new facility, KabiLab D20, at Daimlerstrasse 20 on its Bad Homburg campus, set to cover 5,000 m². This modern laboratory and office building will feature state-of-the-art laboratories, 90 shared workstations, meeting rooms, and storage areas, with relocation planned for mid-2026. Approximately 70 employees from the Fresenius Kabi Business Unit Nutrition will move into the new building to continue developing products such as Fresubin enteral nutrition and a device for patient-specific parenteral nutrition. The facility is part of Fresenius’ efforts to remain a global leader in clinical nutrition, a field expected to grow due to increasing metabolic disorders and chronic diseases like diabetes. Emphasizing sustainability, KabiLab D20 will reuse existing structures to reduce CO₂ emissions, and will be equipped with photovoltaic systems, an efficient heat pump, and rainwater harvesting for irrigation. Additionally, Fresenius plans to relocate an extra 300 employees from Oberursel to the campus by mid-year.

(PRESS RELEASE) BAD HOMBURG, 17-Mar-2025 — /EuropaWire/ — The Fresenius healthcare group is further expanding its innovative product portfolio with the construction of a brand new laboratory and office facility on its campus in Bad Homburg. Located at Daimlerstrasse 20, the state-of-the-art building, dubbed KabiLab D20, will span roughly 5,000 m² and feature modern laboratories, 90 desk-sharing workstations, versatile meeting rooms, and ample storage space. The relocation to this cutting-edge facility is scheduled for mid-2026.

Once operational, approximately 70 employees from the Fresenius Kabi Business Unit Nutrition, currently based in Bad Homburg and Friedberg, will transition into the new building. These teams are heavily involved in the continued development of the Fresubin enteral nutrition portfolio as well as a specialized device designed to produce patient-specific parenteral nutrition. For context, enteral nutrition such as Fresubin is critical for patients who are unable to meet their nutritional needs through regular diets, while parenteral nutrition is an artificial method delivered intravenously, bypassing the gastrointestinal tract. Fresenius stands as the global leader in the field of clinical nutrition, a sector that is expected to see substantial growth in demand due to the rising incidence of metabolic disorders and chronic illnesses like diabetes.

Sustainability is a core focus for the new KabiLab D20. In a bid to minimize its environmental footprint, the project will incorporate parts of the existing building infrastructure, thereby significantly reducing CO₂ emissions compared to constructing a completely new structure. Future enhancements include the installation of photovoltaic systems to generate green electricity, an efficient heat pump for indoor heating, and a rainwater harvesting system to irrigate the new green spaces surrounding the facility.

In addition, Fresenius currently employs approximately 2,100 people in Bad Homburg and another 300 in the nearby town of Oberursel, with plans for the latter group to also relocate to the Bad Homburg campus by mid-year.

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2024 fiscal year, Fresenius generated €21.5 billion in annual revenue. Fresenius currently counts over 175,000 employees. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as an investment in Fresenius Medical Care. With around 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio touches the lives of 450 million patients annually and includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and intravenous generic drugs and fluids. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else KrönerFresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the Company’s website at www.fresenius.com.
Visit our media center: www.fresenius.com/media-center

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in
this release.

Media Contact:

Sabine Polte
Corporate Communications
Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2395
F +49 6172 608-2294
sabine.polte@fresenius.com
www.fresenius.com

SOURCE: Fresenius SE & Co. KGaA